期刊
CURRENT MEDICINAL CHEMISTRY
卷 27, 期 22, 页码 3706-3734出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1573406415666190621094704
关键词
Cancer; p53 Tumor suppressor protein; Mutation; p53-MDM2 protein-protein interaction; Small molecule inhibitors; p53 reactivation
资金
- DST-INSPIRE Fellowship [IF160734]
Cancer is a leading cause of death worldwide. It initiates when cell cycle regulatory genes lose their function either by environmental and/or by internal factors. Tumor suppressor protein p53, known as Guardian of genome, plays a central role in maintaining genomic stability of the cell. Mutation of TP53 is documented in more than 50% of human cancers, usually by overexpression of negative regulator protein MDM2. Hence, reactivation of p53 by blocking the protein-protein interaction between the murine double minute 2 (MDM2) and the tumor suppressor protein p53 has become the most promising therapeutic strategy in oncology. Several classes of small molecules have been identified as potent, selective and efficient p53-MDM2 inhibitors. Herein, we review the druggability of p53-MDM2 inhibitors and their optimization approaches as well as clinical candidates categorized by scaffold type.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据